HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.

Abstract
Bruton's Tyrosine Kinase (BTK) and IL-2 Inducible T-cell Kinase (ITK) are enzymes responsible for the phosphorylation and activation of downstream effectors in the B-cell receptor (BCR) signaling and T cell receptor (TCR) signaling pathways, respectively. Ibrutinib is an FDA-approved potent inhibitor of both BTK and ITK that impairs B-cell and T-cell function. CD4 T cells and B cells are essential for the induction of chronic graft-versus-host disease (cGVHD). We evaluated these targets by testing the ability of Ibrutinib to prevent or ameliorate cGVHD, which is one of the major complications for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We found that Ibrutinib significantly alleviated cGVHD across four different mouse models, accompanied by increased long-term survival and reduced clinical score. The clinical improvements in Ibrutinib-treated recipients were associated with decreased serum-autoantibodies, costimulatory molecule activation, B-cell proliferation, and glomerulonephritis compared to vehicle controls. Ibrutinib was also able to alleviate the clinical manifestations in acute GVHD (aGVHD), where the recipients were given grafts with or without B cells, suggesting that an inhibitory effect of Ibrutinib on T cells contributes to a reduction in both aGVHD and cGVHD pathogenesis. An effective prophylactic regimen is still lacking to both reduce the incidence and severity of human cGVHD following allo-HSCT. Our study shows that Ibrutinib is an effective prophylaxis against several mouse models of cGVHD with minimal toxicity and could be a promising strategy to combat human cGVHD clinically.
AuthorsSteven D Schutt, Jianing Fu, Hung Nguyen, David Bastian, Jessica Heinrichs, Yongxia Wu, Chen Liu, Daniel G McDonald, Joseph Pidala, Xue-Zhong Yu
JournalPloS one (PLoS One) Vol. 10 Issue 9 Pg. e0137641 ( 2015) ISSN: 1932-6203 [Electronic] United States
PMID26348529 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human
  • Btk protein, mouse
  • emt protein-tyrosine kinase
  • Adenine
Topics
  • Adenine (analogs & derivatives)
  • Agammaglobulinaemia Tyrosine Kinase
  • Animals
  • B-Lymphocytes (drug effects)
  • Graft vs Host Disease (drug therapy, enzymology, pathology)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphocyte Activation (drug effects)
  • Mice
  • Piperidines
  • Protein-Tyrosine Kinases (antagonists & inhibitors, biosynthesis)
  • Pyrazoles (administration & dosage, adverse effects)
  • Pyrimidines (administration & dosage, adverse effects)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: